09.09.20

Regenxbio Announces Dosing of First Patient in Phase 2 AAVIATE Trial of RGX-314 for the Treatment of Wet AMD

Source: Regenxbio

08.26.20

ForwardVue Pharma Secures Funding to Advance Preclinical Development Programs

Source: ForwardVue

08.10.20

Clearside Biomedical Announces FDA Acceptance of Investigational NDA for CLS-AX Administered in Suprachoroidal Space

Source: Clearside Biomedical

08.04.20

Regenxbio Announces Additional Positive Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMD

Source: Regenxbio

07.27.20

New Novartis Analysis Examines Sustainable Fluid Control of Beovu Compared With Aflibercept

Source: Novartis

07.22.20

Phase 3 Data Show Port Delivery System With Ranibizumab Enabled Over 98% of Patients to Go 6 Months Between Treatments for Wet AMD

Source: Genentech

07.10.20

Kodiak Sciences Announces New Longer-Term Data from Ongoing Phase 1b Study of KSI-301 in Patients With Retinal Diseases

Source: Kodiak Sciences

07.07.20

Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of Lytenava

Source: Outlook Therapeutics

06.26.20

The FDA Does Not Approve Allergan’s Wet AMD Drug Candidate Abicipar Pegol

Source: Eyewire News

06.24.20

AsclepiX Therapeutics Announces $35 Million Series A Financing

Source: AsclepiX Therapeutics

View more stories